MYC and medulloblastoma: Historical studies have identified biomarkers consistently associated with favorable (β-catenin nuclear immunopositivity as a marker of the WNT medulloblastoma molecular subgroup (MBWNT)) and poor (large-cell/anaplastic (LCA) pathology, MYC gene family amplification) prognosis [2–9], and their retrospective evaluation in the SIOP-UKCCSG-PNET3 clinical trial has validated their use alongside clinical factors for the improved definition of disease risk-stratification groups in disease-wide studies of non-infant medulloblastoma [10].